Actoxumab is a human

monoclonal In biology, monoclonality refers to the state of a line of cells that have been derived from a single clonal origin. Thus, "monoclonal cells" can be said to form a single clone. The term ''monoclonal'' comes . The process of replication can occ ...

antibody designed for the prevention of recurrence of ''

Clostridioides difficile ''Clostridioides difficile'' ( syn. ''Clostridium difficile'') is a bacterium known for causing serious diarrheal infections, and may also cause colon cancer. It is known also as ''C. difficile'', or ''C. diff'' (), and is a Gram-positive spec ...

'' infection. This drug, along with

bezlotoxumab Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infection, ''Clostridioides difficile'' infections. Bezlotoxumab binds to ''Clostridioides di ...

, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the

University of Massachusetts Medical School The UMass Chan Medical School is a public medical school in Worcester, Massachusetts. It is part of the University of Massachusetts system. It consists of three schools: the T.H. Chan School of Medicine, the Morningside Graduate School of Biom ...

. The project was then licensed to Merck & Co., Inc. for further development and commercialization. A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.New treatment for C.diff infections reduces recurrences by 40%, study finds
/ref>

References

Experimental monoclonal antibodies {{monoclonal-antibody-stub